Cryo-Cell International Reports 4% Revenue Decrease to $7.68 Million

Cryo-Cell International, Inc. reported a decrease in revenue for the three months ended February 28, 2026, totaling $7.68 million, down 4% from $7.97 million in the same period last year. The decline was primarily attributed to a 3% decrease in recurring annual storage fee revenue and a 16% drop in the number of new domestic cord blood specimens processed. Processing and storage fees accounted for the majority of revenue at $7.64 million, while product revenue increased to $38,594 from $20,913, and public banking revenue fell sharply to $1,410 from $82,079.

The company's cost of sales decreased by 17% to $1.66 million, compared to $1.98 million in the prior year, reflecting operational efficiencies and reduced costs associated with public banking. However, selling, general, and administrative expenses rose by 8% to $5.01 million, driven largely by legal fees related to ongoing disputes with Duke University, which amounted to approximately $1.23 million. As a result, Cryo-Cell's operating income fell to $765,134 from $1.06 million year-over-year, and net income decreased to $47,108 from $282,855.

In terms of operational metrics, Cryo-Cell's total assets decreased to $60.88 million from $61.73 million, with cash and cash equivalents also declining to $249,672 from $319,031. The company reported a slight increase in accounts receivable, totaling $6.82 million, while total liabilities decreased to $79.29 million from $80.33 million. The company’s stockholders' deficit improved marginally to $18.40 million from $18.61 million.

Strategically, Cryo-Cell continues to focus on its core business of umbilical cord blood and tissue storage, while also navigating the complexities of its licensing agreement with Duke University. The company has faced challenges in expanding its services due to disputes with Duke, which have led to a pause in plans for the Cryo-Cell Institute for Cellular Therapies. The company anticipates that its cash and cash equivalents, along with cash flows from operations, will be sufficient to meet its known cash needs for at least the next 12 months, although future investments related to the Duke agreement remain uncertain pending the outcome of arbitration proceedings.